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A B S T R A C T   
Background and purpose: Tumor hypoxia is an important cause of radioresistance and is associated with poor 
outcome. 
SPECT (Single-photon emission computed tomography) imaging enables visualizing tumor characteristics. We 
investigated the SPECT-radiotracer [111In]-girentuximab-F(ab’)2 to image Carbonic Anhydrase IX (CAIX), an 
enzyme upregulated under hypoxic conditions. 
Materials and methods: Athymic mice with subcutaneous FaDu or SCCNij202 head and neck squamous cell car-
cinoma (HNSCC) xenografts were treated with atovaquone or were housed in a hypoxic chamber (8% O2). Next, 
[111In]-girentuximab-F(ab’)2 was injected and 24 h later mice were euthanized for ex vivo biodistribution, 
autoradiography of the tumor, and immunohistochemical staining of the tumor. Tumor sections were analyzed 
for hypoxia, CAIX expression, vessels, and perfusion. Also, the effect of atovaquone on microSPECT scans was 
determined in the FaDu model. 
Results: Atovaquone decreased CAIX expression by 69% (p = 0.017) compared with control tumors in FaDu, 
while in the SCCNij202 tumors no difference was observed. Hypoxic breathing did not increase CAIX expression 
or hypoxia staining in either tumor model, but did affect the necrotic tumor fraction. Ex vivo tracer uptake in the 
atovaquone treated group did not differ significantly from the control group, despite the difference in CAIX 
expression. Furthermore, SPECT imaging with [111In]-girentuximab-F(ab’)2 did not discriminate atovaquone- 
treated versus control tumors. 
Conclusion: Atovaquone decreased CAIX expression only in the FaDu tumor model. [111In]-girentuximab-F(ab’)2 
specifically targets CAIX-expressing areas in HNSCC xenografts, but differences in vessel density and necrosis 
most likely affected tracer uptake in the tumors and therefore complicated quantification of changes in CAIX 
expression.   
1. Introduction 
Locally advanced head and neck squamous cell carcinomas (HNSCC) 
are treated by surgery and/or radiotherapy, often combined with con-
current chemotherapy. Unfortunately, therapy response is inconsistent, 
resulting in a poor 5-year overall survival of approximately 50% [1]. 
Better predicting and monitoring of therapy response may allow early 
and personalized modification of the treatment plan. 
A prominent predictor of therapy resistance for non-surgical treat-
ments is tumor hypoxia. Both chemotherapy and radiotherapy are less 
effective in tumors with inadequate oxygenation [2,3]. Therefore, the 
hypoxic status of tumors and the development of new anti-hypoxia 
treatments have been subjects of investigation over the past decades. 
Multiple therapies have been evaluated for their potential to 
modulate tumor oxygenation. Breathing of oxygen-enhanced gas mix-
tures (e.g. carbogen) [4], hypoxia mimicking agents (nimorazole) [5], 
hypoxia activated pro-drugs (tirapazamine and TH-302) [6,7], and 
drugs inhibiting oxygen consumption (metformin and atovaquone [17]) 
have been shown to have an effect on tumor hypoxia. Nevertheless, none 
of these treatments became part of clinical practice yet - except for 
nimorazole in Denmark - due to non-conclusive clinical studies, albeit 
that meta-analyses have shown the clinical benefit of hypoxia modifying 
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treatments in combination with radiotherapy [5,8]. 
In the path towards more individualized hypoxia-targeted therapies, 
predictive biomarkers will likely play a substantial role for better se-
lection of such patients. Assessment with molecular imaging has the 
ability to visualize biochemical processes in entire primary tumors and 
metastases. This is crucial for the assessment of hypoxia since it is a 
heterogenous phenomenon between and within tumors. It is heteroge-
neously present within tumors and can change over time due to disease 
progression and therapy. Molecular imaging has the potential to 
repeatedly assess tumor hypoxia and thereby allows making early 
therapy adjustments. For example, if the hypoxic status of a tumor does 
not improve, the selected modification can be adapted. 
PET (positron emission tomography) and SPECT (Single-photon 
emission computed tomography) imaging enables us to visualize tumor 
characteristics. Currently, PET is the most commonly used technique to 
assess tumor hypoxia, making use of 2-nitromidazol-based radiotracers 
(FMISO, FAZA and HX4) [9,10]. Their accumulation mechanism de-
pends on their reductive metabolism, which occurs irreversibly only 
under hypoxic conditions, and thereby entraps the tracer in the hypoxic 
tumor regions. This imaging method has its limitations due to low 
contrast between hypoxic and non-hypoxic subvolumes and its variable 
reproducibility [11]. This lack of reproducibility might be explained by 
the fact that tumor hypoxia is a dynamic phenomenon in time and place. 
Differences in perfusion limited hypoxia may result in differences in 
uptake patterns of 2-nitromidazol-based radiotracers over time. 
A different approach is to image relevant viable radioresistant cells 
in hypoxic tumor areas, by targeting a hypoxia-related antigen 
expressed by tumor cells adapted to hypoxic conditions. A candidate 
antigen for this approach is Carbonic anhydrase IX (CAIX). It is a 
downstream target of the hypoxia inducible factor alpha (HIF1-α) and is 
expressed on the cell membrane in a time frame of several hours after 
onset of hypoxia. Therefore, it represents a subpopulation of cells which 
have adapted to a hypoxic environment. CAIX has been proven to be a 
prognostic biomarker in almost all solid malignancies [12]. 
Previously, our group developed a quantitative CAIX imaging tech-
nique using the SPECT tracer [111In]In-G250-F(ab’)2 [13]. We demon-
strated that this technique can discriminate low CAIX-expressing tumors 
from high CAIX-expressing tumors [14]. Therefore, it could play a pre-
dictive role for treatments where hypoxia is involved in therapy resis-
tance. However, it remains unclear if this radiotracer is also capable of 
detecting changes in the level of CAIX expression within the same tumor 
model. To answer this question, we set up experiments where we 
modulated the level of oxygenation towards an improved oxygenation 
status (atovaquone) and a decreased oxygenation status (hypoxic gas 
breathing) in two different human HNSCC models. We evaluated 
whether this change in oxygenation status altered the CAIX expression 
levels and tumor targeting of [111In]In-G250-F(ab’)2. 
2. Materials and methods 
2.1. Radiotracer production 
[111In]In-G250-F(ab’)2 was produced and radiolabeled as described 
previously [15]. In short, cG250 was enzymatically digested with the 
use of pepsine, resulting in F(ab’)2 antibody fragments. The (Fab’)2 
fragments (110 kDa) were purified and subsequently conjugated with 
diethylenetriamine pentaacetate (DTPA). At days of tracer injection, 
DTPA-G250-F(ab’)2 was radiolabeled with In-111 (Curium, Petten, The 
Netherlands) at an average specific activity of 1.1 MBq/ug. The radio-
chemical purity exceeded 95% in all experiments. 
2.2. Animal models 
Female athymic BALB/c nude mice mice (Janvier Labs, Le Genest- 
Saint-Ile, France) were aged six to eight weeks and weighed 18–22 g 
at the start of the experiments. The animals were housed together in 
filter-topped cages in a specific pathogen-free unit and were included in 
the experiments when tumors had a mean diameter of 5 mm. Stratified 
randomization was used based on tumor size, in order to have a similar 
mean tumor size per study group. The studies were approved by the 
Central Authority for Scientific Procedures on Animals (RU-DEC-2016- 
053) and carried out under supervision of the local Animal Welfare 
Body. 
2.3. Tumor inoculation 
Two HNSCC tumor models were used. The SCCNij202 model is a 
patient-derived HNSCC xenograft model derived from a patient with 
larynx carcinoma. We have previously demonstrated that this is a hyp-
oxic tumor model with high CAIX expression [15]. Mice were implanted 
on the right hind leg with a small (2 mm diameter) tumor chunk excised 
from a donor mouse. The tumors grew to a size of 5–7 mm in circa four to 
five weeks. 
The second tumor model was the FaDu model. This is a well-known 
HNSCC cell line, and is also known to be hypoxic and capable of 
expressing moderate to high levels of CAIX. FaDu cells were cultured at 
37 ◦C with 5% CO2 in medium (DMEM, Sigma) supplement with 10% 
fetal bovine serum. Mice were inoculated subcutaneously with 1 million 
FaDu cells suspended in 50 μl medium and 50 μl Matrigel (BD Bio-
sciences). The tumors grew to a size of 5–7 mm in circa two weeks. 
2.4. Hypoxia modulating treatment 
To modulate tumor oxygenation in tumor-bearing mice, the 
following interventions were performed: Atovaquone and hypoxic 
breathing. Three treatment groups of five mice were evaluated in the 
two different tumor models, resulting in 6 groups in total. Atovaquone 
suspension (Wellvone) 50 mg/kg, to reduce hypoxia by modulating 
mitochondrial function, was administered orally with the use of a 
gavage, daily on 8 consecutive days. Hypoxic breathing setup consisted 
of an airtight cage with an inlet tube and outlet tube. Via the inlet an 8% 
oxygen and 92% nitrogen gas mixture flowed at a minimal rate (155 l/ 
h). The outlet tube had an oxygen sensor which displayed the current 
oxygen percentage on demand. Mice were kept under these conditions 
for 48 h, and only taken out for the i.v. administration of the radiotracer. 
2.5. Biodistribution studies 
Biodistribution studies were performed as described for our previous 
studies with [111In]In-G250-F(ab’)2 [14]. Briefly, all mice were injected 
i.v. with 10 μg [111In]In-G250-F(ab’)2 (1 MBq) diluted with PBS 0.5% 
BSA to a volume of 200 μl, on the second to last day of treatment and 24 
h before euthanasia. Mice were euthanized by CO2/O2 inhalation and 
tumors and normal tissues were collected. Half of the tumor was used for 
biodistribution analysis, while the other half was used for immunohis-
tochemistry and autoradiography. Samples were weighed and subse-
quently the radioactivity in the tissue samples was determined in a 
γ-counter (2480 Wizard 3′′, LKB/Wallace, Perkin-Elmer, Boston, MA). 
Activity concentrations in the tissues were calculated as percentage of 
the injected dose per gram of tissue (%ID/g). Tracer injection standards 
were measured simultaneously for decay correction. 
2.6. MicroSPECT imaging 
In a separate experiment 10 other animals were used for the acquired 
SPECT scans. These mice, bearing a FaDu tumor, were allocated to one 
of two groups (n = 5 each); a control group and an atovaquone treat-
ment group. The procedure was similar to the first experiment, except 
mice were scanned with microSPECT at 23 h after injection with 10 μg 
[111In]In-G250-F(ab’)2 (10 MBq). Images were acquired with micro-
SPECT (U SPECT-II; MILabs, Utrecht, The Netherlands). Animals were 
anesthetized with isoflurane and the tumor region (to maximize signal) 
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was scanned in prone position using a 1.0 mm diameter multipinhole 
mouse collimator. Scans were acquired for 50 min using twelve bed 
positions. Scans were reconstructed using MILabs reconstruction soft-
ware with five iterations, sixteen subsets and an algorithm with a voxel 
size of 0.375 mm. Subsequently, SPECT images were analyzed with 
Inveon Research Workplace software (version 3.0; Siemens Preclinical 
Solutions). 
2.7. Immunohistochemistry and autoradiography 
Half of the excised tumors were immediately snap-frozen in liquid 
nitrogen and cut into 5 µm sections. Subsequently, tissue sections were 
mounted on poly-l-lysine coated slides. Sections were fixed with cold 
acetone for 10 min at 4 ◦C. For every tumor, marked sections were 
analyzed by autoradiography and immunohistochemical staining. 
Overnight, sections were exposed to a phospholuminescence plate in a 
Fujifilm BAS cassette 2025 (Fuji Photo Film), after which the plates were 
scanned with a BAS-1900 II bioimaging analyzer and analyzed with Aida 
Image Analyzer software (Raytest). Then, slides were stored at − 80 ◦C. 
Immunohistochemical staining for CAIX, hypoxia (pimonidazole), ves-
sels and perfusion (Hoechst 33342) was performed as described previ-
ously Hoeben et al. [16]. Staining for hypoxia and CAIX was quantified 
in fraction of the viable tumor area multiplied by the signal intensity, 
thereby taking in to account both the number of CAIX positive cells and 
the intensity of the staining. Necrotic fractions were determined as 
fraction of the total tumor area with the help of H&E staining of 
consecutive tumor sections [16]. 
2.8. Statistics 
Graphpad Prism 6 was used for statistical analyses. Data were pre-
sented as mean and standard deviation. Statistical significance was 
determined with the one-way ANOVA. The Dunnett’s correction was 
used in case of multiple testing. Correlation was assessed by using the 
Pearson test. A p-value of <0.05 was used to determine significance. 
3. Results 
3.1. Modulation of hypoxia and CAIX by atovaquone and low oxygen gas 
breathing 
Immunohistochemical analyses showed a significant lower staining 
for CAIX (p = 0.017) and pimonidazole staining (p = 0.007) in 
atovaquone-treated FaDu tumors compared with non-treated FaDu tu-
mors. The control group had a CAIX staining (fraction × mean intensity) 
of 1.89 × 106 versus 5.94 × 105 for the treated group: a reduction of 
69%. Pimonidazole staining (fraction × mean intensity) was 5.60 × 106 
in the control group and 1.93 × 105 for the group treated with atova-
quone, a reduction of 66%. Immunohistochemical analyses of the 
SCCNij202 tumors did not show a significant difference in pimonidazole 
and CAIX staining of treated and non-treated tumors (Fig. 1A and B). 
Atovaquone treatment did not have a significant effect on the Hoechst 
perfused fraction of the tumor in both models, but we did find a sig-
nificant increase in vessel density in the FaDu model (p = 0.04) (Fig. 1C 
and D). 
Hypoxic breathing decreased CAIX staining significantly and was 
3.7 × 105 compared with 1.89 × 106 for control FaDu tumors (p < 0.05), 
Fig. 1. Immunohistochemical analysis of the tumors in the 3 treatment groups in both the FaDu and SCCNij202 tumor models. CAIX staining and pimonidazole 
staining are expressed in fraction of the viable tumor × mean signal intensity. (A) CAIX expression, (B) pimonidazole, (C) Vessel density (vessels per mm2) and (D) 
Perfused fraction. Graph bars represent mean ± SD (n = 3–5). 
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a reduction of 70%. Pimonidazole staining also showed a significantly 
lower signal with 1.80 × 106 compared with 5.60 × 106 (p < 0.05); a 
reduction of 80% (Fig. 1A and B). Furthermore, FaDu tumors showed a 
significantly higher necrotic fraction for the hypoxic breathing group 
compared with the control group (0.40 versus 0.72) (p < 0.01). The 
necrotic fraction in the atovaquone group (0.31) did not differ signifi-
cantly from the control group (Figs. 2B and 3). 
3.2. Tracer uptake in the tumor did not increase after atovaquone 
treatment 
Tumor tracer uptake in non-treated tumors was 5.61 ± 1.79%ID/g 
and 2.59 ± 0.47%ID/g for FaDu and SCCNij202, respectively. Atova-
quone treatment did not result in a decreased [111In]In-G250-F(ab’)2 
tracer accumulation in either tumor model and resulted in uptake of 
5.71 ± 1.23 and 2.05 ± 0.20%ID/g for FaDu and SCCNij202, respec-
tively. In the groups treated with hypoxic breathing, tumor accumula-
tion was significantly lower for the FaDu model with 1.92 ± 0.42%ID/g 
(p < 0.01) and lower but not significant for the SCCNij202 group with 
1.71 ± 0.73%ID/g (p = 0.10) (Fig. 4). Irrespective of treatment, tumor 
accumulation of [111In]In-G250-F(ab’)2 (%ID/g) moderately correlated 
to the level of CAIX staining for all the individual FaDu tumors, with a 
correlation coefficient of r = 0.49 (p = 0.08) (Sup. Fig. 1). 
3.3. SPECT imaging did not allow for discrimination of atovaquone- 
treated versus control tumors 
SPECT imaging demonstrated a heterogenous uptake of [111In]In- 
G250-F(ab’)2 in the FaDu tumors. The pattern of tracer uptake in the 
autoradiography images was similar to the CAIX expression pattern as 
shown immunohistochemically. Apart from this similar pattern, a high 
signal was observed in non-CAIX-expressing tumor areas as well. No 
obvious difference in signal intensity was seen between the atovaquone 
treatment group and the control group (Figs. 5 and 6). 
Fig. 2. Immunohistochemistry images of all tested 
conditions. Stained tumor sections of the FaDu model 
are depicted on the top row as (A) control, (B) after 
48 h of 8% oxygen breathing, and (C) after 8 days of 
atovaquone treatment. On the bottom row, tumor 
sections of the SCCNij202 model with treatment 
groups are depicted in the same order. Tumor sections 
were stained for CAIX in red, pimonidazole in green 
and vessels in blue. (For interpretation of the refer-
ences to colour in this figure legend, the reader is 
referred to the web version of this article.)   
Fig. 3. Necrotic fractions of the FaDu tumor model of all 3 treatment groups: 
control, hypoxic breathing and atovaquone, calculated as fraction of the com-
plete tumor area. Graph bars represent mean ± SD (n = 5). 
Fig. 4. Biodistribution results of tumor tracer uptake 24 h after injection of 
[111In]-girentuximab-F(ab’)2 (ID/g) in all 3 treatment groups in both the FaDu 
and SCCNij202 model. Graph bars represent mean ± SD (n = 3–5). 
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4. Discussion 
In this study we explored the application of the tracer [111In]In- 
G250-F(ab’)2 to assess the changes in CAIX expression induced by 
hypoxic gas breathing (meant to induce hypoxia and hence increase 
CAIX expression) and inhibition of mitochondrial respiration with ato-
vaquone to reduce hypoxia (and reduce CAIX expression) in human 
xenografted HNSCC. We showed that atovaquone treatment reduced 
tumor hypoxia and CAIX expression in one of the two HNSCC models 
investigated. However, this reduction could not be detected by CAIX- 
imaging with [111In]In-G250-F(ab’)2. Furthermore, we found that ato-
vaquone affected the vessel density and hypoxic breathing affected the 
amount of necrosis. Our data suggest that changes in vessel density or 
blood perfusion induced by the treatment may hamper the applicability 
of [111In]In-G250-F(ab’)2 for monitoring tumor hypoxia. Lastly, this 
study demonstrates that, while investigating hypoxia and tumor accu-
mulation of radiotracers, equal pharmacodynamic conditions of test 
subjects is of vital importance. 
In the FaDu model, atovaquone treatment resulted in a decrease of 
roughly 40% in hypoxia and CAIX expression, as measured by pimoni-
dazole and CAIX immunohistochemical staining. This decrease was 
significant for both CAIX and pimonidazole, but was lower than ex-
pected. This difference is not as large as was described by McKenna et al. 
who measured a decrease of hypoxia of up to 90% in a FaDu xenograft 
model [17]. Atovaquone was administered with the same dosing- 
schedule as was used by McKenna et al. We treated mice for seven 
consecutive days with atovaquone, which should be long enough to 
account for the long half-life is the CAIX protein. Interestingly, the effect 
of hypoxia-modulating treatments was not equal in both tumor models. 
Especially, treatment with atovaquone did not achieve a reduction of 
hypoxia or CAIX expression in the SCCNij202 model, although both 
models express similar amounts of hypoxia and CAIX in the control tu-
mors. This underlines the differential responses that can be present to 
atovaquone hypoxia modulation between different tumors. 
Our hypoxic breathing treatment (48 h, 8% O2) did not increase 
hypoxia nor CAIX expression. Of note, mice that were exposed to hyp-
oxic breathing, did not eat and drink properly and lost body weight due 
to dehydration. This may have resulted in altered pharmacokinetics and 
altered perfusion of the tumors, as demonstrated by significantly altered 
kidney and liver accumulation of the radiotracer and enhanced necrosis 
in the viable tumor tissue (Supl. Fig. 3). This effect on tumor necrosis has 
not been reported elsewhere. The increased tumor necrosis in this group 
hinders reliable immunohistochemical analysis and is likely the cause of 
the unexpected decrease in hypoxia and CAIX expression. Together, this 
makes the results from this treatment group difficult to interpret. We 
were not able to determine the necrotic fractions in the SCCNij202 line 
due to high amount of keratinization (Sup. Fig. 2). 
Overall ex vivo tracer uptake in FaDu tumors showed a modest 
correlation with CAIX expression. However, despite the reduction of 
CAIX expression in the FaDU model, tumor tracer uptake did not 
Fig. 5. (A) and (C) show a combined immunohistochemistry staining for CAIX (red), tissue perfusion (blue) and vessels (green) as visualized with Hoechst. (B) and 
(D) are ex vivo autoradiography images showing the 2D uptake of [111In]-girentuximab-F(ab’)2 . (For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of this article.) 
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decrease in the groups treated with atovaquone. High accuracy of 
quantitative CAIX assessment is warranted to enable detection of slight 
alterations in CAIX expression. Unfortunately, tumor accumulation of 
radiotracers is dependent on more variables than the amount of target 
antigen expressed in a tumor. As described by Xenaki et al. both tumor 
characteristics and tracer characteristics play a role in the amount of 
tracer accumulation in the tumor. Besides antigen availability, the main 
factors within a tumor are vessel density, vessel permeability, perfusion 
rate, perfusion volume and necrosis. As shown in Fig. 1, atovaquone 
treatment also influenced the vessel density of the FaDu model. With this 
influence on the tumor vasculature it is possible that atovaquone 
treatment also has influence on vascular permeability. Vascular 
permeability is known to be associated with an enhanced permeability 
and retention effect (EPR-effect) [18,19]. Therefore, effects of atova-
quone may have resulted in enhanced permeability and could be 
responsible for the higher ex vivo tracer uptake observed in our study, 
thereby masking a decrease in CAIX expression. 
Our previous study on [111In]In-G250-F(ab’)2 demonstrated the 
capability to discriminate between low and high CAIX-expressing tu-
mors, but also showed a significant level of non-specific uptake at 24 h p. 
i. The EPR effect has shown to be size-dependent and affects molecules 
larger than ~ 40 kDa, and thus affects F(ab’)2 which has a size of 110 
kDa. As a result, the non-specific tracer uptake will hinder the accuracy 
of the CAIX quantification using these tracers particularly, when the 
vascular permeability changes due to therapeutic intervention. Even 
smaller radiotracers such as nanobody-based or affibody-based mole-
cules are less affected by the EPR-effect [14,20]. Future studies could 
investigate CAIX-targeting radiotracers based on nanobodies and test 
them in a similar hypoxia modifying experiment as presented here. 
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